EGFR and non-small cell lung carcinoma: In addition, a randomized phase III trial (TIGER-3) showed that rociletinib has longer progression-free survival but higher rates of hyperglycemia compared to chemotherapy in advanced-NSCLC patients with mutated EGFR (excluding exon 20 insertion) [155].